Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

NANJING, China, Nov. 23, 2023 /PRNewswire/ — On November 21, 2023, Simcere Pharmaceutical Group Limited (“Simcere”) entered into an exclusive license and collaboration agreement (the “Agreement”) with Connect Biopharma HongKong Limited (“Connect”) in relation to Rademikibart, an…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.